Nesapidil
Nesapidil is an antiarrhythmic agent and calcium channel blocker. Nesapidil slows calcium channel activity, which in turn causes slowing of atrioventricular conduction and sinus heart rate. Nesapidil alters preload, afterload, contractility, and coronary blood flow. Nesapidil can be used in research related to arrhythmia and hypertension.
For research use only. We do not sell to patients.
- CAS No.: 90326-85-5
- Formula: C23H28N4O4
- Molecular Weight:424.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Calcium Channel Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 90326-85-5
-
Molecular Weight 424.50
-
Formula C23H28N4O4
-
SMILES
OC(COC1=CC=CC(=C1)C2=NN=C(O2)C)CN3CCN(C=4C=CC=CC4OC)CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cardiac voltage-sensitive optical mapping
Cardiac voltage-sensitive optical mapping records changes in transmembrane potential from cardiac tissue by staining the preparation with a voltage-sensitive dye and imaging fluorescence changes during electrical activation; the resulting optical action potentials can be used to map activation time, action potential duration, conduction velocity, wavefront propagation, and arrhythmia dynamics. The optical signal represents a relative fluorescence change from a tissue volume rather than a single-cell intracellular recording, so spatial resolution, sampling rate, voltage resolution, optical magnification, light penetration, and motion control must be considered together when interpreting optical action potentials.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)